Oophorectomy and breast cancer in BRCA mutation carriers--letter.

نویسنده

  • Franco Berrino
چکیده

The article by Kotsopoulos and colleagues (1) shows that oophorectomy significantly decreased the incidence of breast cancer in carriers of deleterious BRCA mutations, with OR, 0.52 [95% confidence interval (CI), 0.40–0.66]. This is an important result. The authors, however, wrongly interpreted their results writing that "women who underwent surgical menopause had a 48% decrease in the risk of developing breast cancer." An OR, in fact, is a good estimate of the relative risk (i.e., the risk ratio) only if the disease is rare, but in mutation carriers, the disease is very frequent. The source population actually included about 4,000 cases of 5,000 women, a proportion fairly consistent with the estimated penetrance of BRCA mutations. With such a large proportion of cases in the source population, the unbiased risk ratio could be of the order of 0.67, corresponding to 33% decrease in breast cancer risk, still a major effect. The same flawed interpretation was present in several previous articles from the same group.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Use of systemic hormone therapy in BRCA mutation carriers.

As more women are being counseled and tested, clinicians increasingly encounter women with identified BRCA1 and BRCA2 gene mutations. Existing, albeit limited, data indicate that risks of breast cancer are not increased with use of systemic hormone therapy by menopausal BRCA mutation carriers with intact breasts. Young mutation carriers with or without intact breasts should not defer or avoid r...

متن کامل

Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.

IMPORTANCE Women who carry a germline mutation in either the BRCA1 or BRCA2 gene face a lifetime risk of breast cancer of up to 70%, and once they receive a diagnosis of breast cancer, they face high risks of both second primary breast and ovarian cancers. Preventive bilateral salpingo-oophorectomy is recommended to women with a BRCA mutation at age 35 years or thereafter to prevent breast and ...

متن کامل

Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.

Germline mutations in BRCA1 or BRCA2 genes redispose to hereditary breast and ovarian cancers. he estimated lifetime risk of breast cancer in BRCA1 utation carriers ranges from 50% to 80%, while the stimated lifetime risk of ovarian cancer ranges from 0% to 65%. Although breast cancer risk is similar in omen who inherit BRCA2 mutations, the lifetime risk f ovarian cancer is approximately 20% [1...

متن کامل

Primary peritoneal cancer in BRCA carriers after prophylactic bilateral salpingo-oophorectomy.

OBJECTIVE The presence of deleterious mutations in breast cancer (BRCA)-1 or BRCA-2 gene has a decisive influence on the development of various types of neoplasms, such as breast, ovarian, tubal, and peritoneal cancers. Primary peritoneal cancer is an aggressive malignancy which, due to the absence of a specific screening test, cannot be diagnosed in its early stages. As a risk-reducing option,...

متن کامل

Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice

BRCA deficiency predisposes to the development of invasive breast cancer. In BRCA mutation carriers this risk can increase up to 80%. Currently, bilateral prophylactic mastectomy and prophylactic bilateral salpingo-oophorectomy are the only preventive, albeit radical invasive strategies to prevent breast cancer in BRCA mutation carriers. An alternative non-invasive way to prevent BRCA1-associat...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

دوره 21 8  شماره 

صفحات  -

تاریخ انتشار 2012